Products
Online Inquiry
TAK-632
Cat. No.:
0225LY-0662
Appearance:
Solid
Purity:
≥99%
Identity:
Confirmed by NMR, and LC-MS.
Size:
Add to basket
Product Overview
Description:
TAK-632 is a high-purity (99%) pan-Raf inhibitor that appears as an off-white solid with a melting point of 178-182 degrees Celsius; it has a molecular weight of 362.4 and is soluble in DMSO up to 100mM.
Synonym:
1228591-30-7; N-(7-cyano-6-(4-fluoro-3-(2-(3-(trifluoromethyl)phenyl)acetamido)phenoxy)benzo[d]thiazol-2-yl)cyclopropanecarboxamide; N-[7-cyano-6-[4-fluoro-3-[[2-[3-(trifluoromethyl)phenyl]acetyl]amino]phenoxy]-1,3-benzothiazol-2-yl]cyclopropanecarboxamide; Benzeneacetamide, N-[5-[[7-cyano-2-[(cyclopropylcarbonyl)amino]-6-benzothiazolyl]oxy]-2-fluorophenyl]-3-(trifluoromethyl)-; compound 8B [PMID: 23906342]; N-[5-[[7-cyano-2-[(cyclopropylcarbonyl)amino]-6-benzothiazolyl]oxy]-2-fluorophenyl]-3-(trifluoromethyl)-benzeneacetamide
CAS No.:
1228591-30-7
Compound CID:
46209401
Formula:
C27H18F4N4O3S
Formula Weight:
554.52
Specification
Targets&IC50:
B-Raf: 8.3 nM; C-Raf: 1.4 nM; Aurora B: 66 nM; FGFR3: 280 nM; PDGFRβ: 120 nM
Relative Density:
1.52 g/cm3
Stability:
3 years in powder form.
Storage:
Storage at -20°C.
Applications:
TAK-632 can be used in cancer biology to study the pan-Raf inhibition in tumors with BRAF or RAS mutations.
Library Information
Target:
PDGFR; Aurora kinase; Raf; FGFR
Receptor:
Aurora B; Aurora kinase; B-Raf; C-Raf; FGFR3; PDGFRβ; Raf
Pathways:
Angiogenesis; Chromatin/Epigenetic; MAPK; Cell cycle/Checkpoint; Tyrosine kinase/adaptors
Plate Number:
AOCL-9
Plate Location:
e8
Empty Location:
a1-h1; a12-h12
Container:
96-well plate
Formulation:
10mM DMSO
DMSO Max Solubility:
93 mg/mL; 167.71 mM
Water Max Solubility:
<1 mg/mL (insoluble or slightly soluble)
Ethanol Max Solubility:
2 mg/mL; 3.61 mM
ALogP:
5.74
HBA_Count:
4
HBD_Count:
2
Rotatable Bond:
8
